[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645156":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":64,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Pest County Flór Ferenc Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients receiving hemoadsorption treatment",null,"Criticall ill patients who received hemoadsorption therapy using CytoSorb or Efferon LPS between January 1 2020 and May 31 2026",[13],"Procedure: Hemoadsorption",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Hemoadsorption","Patients included in this retrospective observational study received adjunctive hemoadsorption therapy as part of routine clinical care at the discretion of the treating intensive care physicians. Hemoadsorption was performed using either the CytoSorb® or Efferon LPS® hemoadsorption cartridge, according to the clinical indication and device availability.\n\nHemoadsorption was integrated into a continuous renal replacement therapy (CRRT) circuit. Treatment duration, number of hemoadsorption sessions, timing of therapy initiation, and concomitant intensive care interventions were determined by the treating physicians and were not influenced by the study protocol.\n\nNo study-specific interventions, additional diagnostic procedures, or protocol-mandated treatments were performed.",[9],[21],{"name":22,"affiliation":5,"role":23},"Zoltán Ruszkai, MD, PhD","STUDY_DIRECTOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","0036209151978","ruszkai.zoltan@florhosp.hu",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":31},"Gergely Bokrétás, MD","bokretas.gergely@florhosp.hu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Pest County Flór Ferenc Hospital, Dept. of Anaesthesiology and Intensive Therapy","RECRUITING","Kistarcsa","Pest County","2143","Hungary","HU",{"type":42,"coordinates":43},"Point",[44,45],19.26247,47.54757,{"lat":45,"lon":44},[48,49,50,52,54,56,58,60,62],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":30,"role":26,"phone":10,"phoneExt":10,"email":31},{"name":22,"role":51,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":30,"role":53,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":55,"role":53,"phone":10,"phoneExt":10,"email":10},"Csanád Geréd, MD",{"name":57,"role":53,"phone":10,"phoneExt":10,"email":10},"Dóra Jakab, MD",{"name":59,"role":53,"phone":10,"phoneExt":10,"email":10},"Zsuzsanna Katona, MD",{"name":61,"role":53,"phone":10,"phoneExt":10,"email":10},"Eszter Mátrai, MD",{"name":63,"role":53,"phone":10,"phoneExt":10,"email":10},"Barnabás Simon, MD",{"type":51,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zoltan Ruszkai, MD, PhD","Head of Department of Anesthesiology and Intensive Therapy","100645156","hemodynamic-laboratory-and-clinical-outcomes-of-hemoadsorption-therapy-an-observational-study-at-flr-ferenc-hospital-using-longitudinal-data-100645156",false,"NCT07679555","Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption theraPy: an obsErvational Study at Flór Ferenc Hospital Using Longitudinal Data","Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption theraPy: an obsErvational Study at Flór Ferenc Hospital Using Longitudinal Data (HOPE-FUL)","HOPE-FUL","Inclusion Criteria:\n\n* \\>18 years;\n* CytoSorb or Efferon LPS hemoadsorption treatment,\n* with available relevant pre- and post-treatment clinical and laboratory data\n\nExclusion Criteria:\n\n* age under 18 years\n* missing key demographic or outcome data;\n* unknown treatment type or timing;\n* data unavailable for legal or ethical reasons.","ALL","18 Years",{"count":78,"type":79},60,"ESTIMATED","OBSERVATIONAL","This single-center retrospective observational cohort study aims to evaluate the clinical, hemodynamic, and laboratory effects of adjunctive hemoadsorption therapy in critically ill adult patients treated in the Intensive Care Unit of Flór Ferenc Hospital, Hungary, between January 1, 2020, and May 31, 2026. Patients who received CytoSorb or Efferon LPS hemoadsorption therapy will be included.\n\nThe study will assess changes in vasopressor requirements, hemodynamic parameters, inflammatory biomarkers, liver function tests, tissue perfusion markers, and oxygenation following hemoadsorption treatment. Clinical outcomes, including intensive care unit length of stay, ICU mortality, and 28-day and 90-day mortality, will also be evaluated. Data will be collected retrospectively from anonymized medical records, and no study-related interventions will be performed.",[17,83],"Vasopressor Therapy",[85,86,87,88,89,90,91],"hemoadsorption","CytoSorb","Efferon LPS","Vasoactive Inotropic Score","Vasopressor Dependency Index","Shock reversal time","Biomarkers","2026-06-25",{"date":94,"type":95},"2026-07-01","ACTUAL",{"date":97,"type":95},"2020-01-01",{"date":99,"type":79},"2026-09-30",{"name":5,"class":6},1]